This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
This comparison highlights which option tends to exhibit higher or lower risk in retirement contexts, with practical takeaways.
24,580 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Small-cap healthcare stocks are gaining traction in 2026 as trial milestones and funding flow refresh investor intere...
Portfolio manager Ben Carlson argues that avoiding big-ticket upgrades can shield households and portfolios from infl...
The Strategic Petroleum Reserve sits near a 40-year low, yet Wall Street focuses on production and demand signals rat...
Bitcoin trades near a critical threshold as Grayscale signals potential value on-chain. This report weighs whether bi...
A high-profile Texas ruling removed Roc Nation from a cluster of lawsuits linked to a celebrity legal fight. This art...
Netflix has fallen sharply, but a trough like this can hide opportunity. This guide breaks down what drove the declin...
Thinking Machines launches Inkling, its inaugural broad-use AI model. The move highlights a shift toward accessible A...
A drone leader sparked fresh optimism as AeroVironment stock took flight this week, jumping on news of real-world cou...
Tension in the Middle East threatens to throttle energy flows, with oil and gas markets reacting as investors reasses...
VR Adviser recently disclosed a substantial sale of Ocular Therapeutix shares, triggering questions about what it mea...
The YieldMax PYPL Option Income Strategy ETF is under pressure as its strategy to harvest option premiums collides wi...